Charles River, Takeda announce scientific collaboration to identify and develop preclinical candidates

This article was originally published here

Together, Charles River and Takeda will launch multiple integrated programs across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience, and rare disease—with the ultimate goal of delivering preclinical candidates

The post Charles River, Takeda announce scientific collaboration to identify and develop preclinical candidates appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply